Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification or EFGR Activating Mutations.

NCT00748709 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT00748709
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00748709 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification or EFGR Activating Mutations.
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2
Overall status
Terminated
Start date
October 1, 2008
Completion date
Not reported
Enrollment
20 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms